Clinical Trial Update: APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update reporting results for APR-246 in combination with azacitidine for TP53-mutated acute myeloid leukemia or myelodysplastic syndromes…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• APR-246 (eprenetapopt)
• AZACITIDINE (AZACITIDINE)

Snippet

Sponsor: Aprea Therapeutics | Conditions: Acute Myeloid Leukemia or Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED | Results posted: 2024-03-26